Timed, sustained release systems for propranolol
First Claim
1. A timed, sustained-release (TSR) pharmaceutical formulation comprising timed, sustained release beads, wherein said TSR beads comprise:
- a) a core comprising propranolol or a pharmaceutically acceptable salt thereof;
b) a first membrane comprising a first water insoluble polymer surrounding said core;
c) a second outer membrane comprising a mixture of a second water insoluble polymer and an enteric polymer;
wherein said formulation provides a lag time in propranolol blood plasma concentration of about 2 to about 6 hours,wherein said formulation comprises about 80 mg, about 120 mg, or about 160 mg of propranolol or a pharmaceutically acceptable salt thereof,wherein said formulation provides a maximum blood plasma concentration (Cmax) between about 10 and about 14 hours following administration.
11 Assignments
0 Petitions
Accused Products
Abstract
A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
225 Citations
19 Claims
-
1. A timed, sustained-release (TSR) pharmaceutical formulation comprising timed, sustained release beads, wherein said TSR beads comprise:
-
a) a core comprising propranolol or a pharmaceutically acceptable salt thereof; b) a first membrane comprising a first water insoluble polymer surrounding said core; c) a second outer membrane comprising a mixture of a second water insoluble polymer and an enteric polymer; wherein said formulation provides a lag time in propranolol blood plasma concentration of about 2 to about 6 hours, wherein said formulation comprises about 80 mg, about 120 mg, or about 160 mg of propranolol or a pharmaceutically acceptable salt thereof, wherein said formulation provides a maximum blood plasma concentration (Cmax) between about 10 and about 14 hours following administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
Specification